Physician profile
Brian Chan Kai
NPI 1578690566
$154,973.78
in general payments reported to CMS, 2019-2025
24 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,822 · 2021: $3,958 · 2022: $11K · 2023: $30K · 2024: $40K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Travel and Lodging: $5,614 · Food and Beverage: $4,853 · Honoraria: $3,000 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,052.81 |
| Consulting Fee | $17,141.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,096.00 |
| Travel and Lodging | $5,614.04 |
| Food and Beverage | $4,853.11 |
| Honoraria | $3,000.00 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $57,822.34 | 2023-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $38,946.30 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $15,119.59 | 2019-2022 | |
| Abbvie INC. | $12,833.52 | 2022-2025 | Ozurdex |
| Genentech USA, INC. | $11,043.90 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Allergan, INC. | $6,080.25 | 2019-2021 | |
| Baxter Healthcare | $5,100.00 | 2022-2023 | Hillrom - Retinavue Network, Hillrom - Retinavue 700 Imager |
| Harrow Eye, LLC | $3,522.54 | 2025 | Triesence, Iheezo |
| Genentech, INC. | $2,064.99 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Astellas Pharma US INC | $720.37 | 2023-2025 | Izervay |
| Alcon Vision LLC | $470.40 | 2022-2023 | Constellation, Ngenuity |
| Bausch & Lomb Americas INC. | $309.34 | 2022-2023 | Vyzulta, Stellaris Elite, Xiidra |
| Regeneron Pharmaceuticals, INC. | $211.71 | 2025 | Eylea Hd, Eylea |
| Ocular Therapeutix, INC. | $173.36 | 2025 | Dextenza |
| Alimera Sciences, INC. | $154.44 | 2024 | Yutiq, Iluvien |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Ani Pharmaceuticals, INC. | $119.48 | 2025 | Yutiq |
| Sandoz INC. | $78.81 | 2025 | Cimerli |
| Topcon Healthcare, INC. | $52.44 | 2025 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chan Kai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.